Cancer Evolution: A Multifaceted Affair.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
06 Dec 2023
Historique:
received: 04 05 2023
revised: 29 08 2023
accepted: 23 10 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: aheadofprint

Résumé

Cancer cells adapt and survive through the acquisition and selection of molecular modifications. This process defines cancer evolution. Building on a theoretical framework based on heritable genetic changes has provided insights into the mechanisms supporting cancer evolution. However, cancer hallmarks also emerge via heritable nongenetic mechanisms, including epigenetic and chromatin topological changes, and interactions between tumor cells and the tumor microenvironment. Recent findings on tumor evolutionary mechanisms draw a multifaceted picture where heterogeneous forces interact and influence each other while shaping tumor progression. A comprehensive characterization of the cancer evolutionary toolkit is required to improve personalized medicine and biomarker discovery. Tumor evolution is fueled by multiple enabling mechanisms. Importantly, genetic instability, epigenetic reprogramming, and interactions with the tumor microenvironment are neither alternative nor independent evolutionary mechanisms. As demonstrated by findings highlighted in this perspective, experimental and theoretical approaches must account for multiple evolutionary mechanisms and their interactions to ultimately understand, predict, and steer tumor evolution.

Identifiants

pubmed: 38047596
pii: 731491
doi: 10.1158/2159-8290.CD-23-0530
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

OF1-OF13

Informations de copyright

©2023 The Authors; Published by the American Association for Cancer Research.

Auteurs

Giovanni Ciriello (G)

Swiss Cancer Center Leman, Lausanne, Switzerland.
Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.

Luca Magnani (L)

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
Breast Epigenetic Plasticity and Evolution Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Sarah J Aitken (SJ)

Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Leila Akkari (L)

Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Sam Behjati (S)

Wellcome Sanger Institute, Hinxton, United Kingdom.
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom.

Douglas Hanahan (D)

Swiss Cancer Center Leman, Lausanne, Switzerland.
Ludwig Institute for Cancer Research, Lausanne, Switzerland.

Dan A Landau (DA)

New York Genome Center, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.

Nuria Lopez-Bigas (N)

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Darío G Lupiáñez (DG)

Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany.

Jean-Christophe Marine (JC)

Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Ana Martin-Villalba (A)

Department of Molecular Neurobiology, German Cancer Research Center (DFKZ), Heidelberg, Germany.

Gioacchino Natoli (G)

Department of Experimental Onco-logy, European Institute of Oncology IRCCS, Milan, Italy.

Anna C Obenauf (AC)

Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.

Elisa Oricchio (E)

Swiss Cancer Center Leman, Lausanne, Switzerland.
Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

Paola Scaffidi (P)

Department of Experimental Onco-logy, European Institute of Oncology IRCCS, Milan, Italy.
Cancer Epigenetic Laboratory, The Francis Crick Institute, London, United Kingdom.

Andrea Sottoriva (A)

Computational Biology Research Centre, Human Technopole, Milan, Italy.

Alexander Swarbrick (A)

Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, Australia.
School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.

Giovanni Tonon (G)

Vita-Salute San Raffaele University, Milan, Italy.
Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Sakari Vanharanta (S)

Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Johannes Zuber (J)

Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.
Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria.

Classifications MeSH